India Pharma Outlook Team | Wednesday, 10 June 2026
The U.S. Food and Drug Administration (FDA) has accepted Takeda’s supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO (vedolizumab) to treat moderately to severely active ulcerative colitis (UC) and Crohn’s disease in pediatric patients aged two years and older.
The regulatory milestone marks a significant advancement in the treatment of pediatric Inflammatory Bowel Disease (IBD), an area where therapeutic options have historically remained limited. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in the first quarter of 2027.
“A child or teen diagnosed today with UC or Crohn’s disease has decades of medical treatment ahead and represents one of the most challenging to treat patient populations in pediatric gastroenterology. Yet, historically, therapeutic options for this age group have been limited,” said Chinwe Ukomadu, MD, PhD, Senior Vice President and Head - Gastrointestinal & Inflammation Therapeutic Area Unit.
Ulcerative colitis and Crohn’s disease are the two most common forms of inflammatory bowel disease and are characterized by chronic inflammation of the gastrointestinal tract. Approximately one in four IBD patients is diagnosed before the age of 20, and the prevalence of these conditions among children and adolescents continues to rise globally.
Also Read: FDA Expands EBGLYSS Dosing to Just 6 Injections a Year
If approved, ENTYVIO would become the only gut-focused treatment option available for pediatric patients with moderately to severely active UC and Crohn’s disease. The biologic therapy specifically targets inflammation in the gastrointestinal tract by binding to the α4β7 integrin and blocking its interaction with MAdCAM-1, a molecule primarily expressed in the gut.
Takeda’s application is supported by data from two Phase III pediatric clinical trials, the KEPLER study in ulcerative colitis and the ongoing WEBB study in Crohn’s disease. These studies evaluated the efficacy and safety of vedolizumab in patients aged between two and 17 years, helping strengthen the evidence base for its use in younger populations.
The FDA acceptance follows Takeda’s broader strategy to expand ENTYVIO’s reach across international markets. The company has already submitted a marketing authorization application to the European Medicines Agency for the same pediatric indication and plans to file in additional markets during the year.
ENTYVIO is currently approved for adults with moderately to severely active ulcerative colitis and Crohn’s disease and has received regulatory approvals in more than 80 countries for intravenous administration. Globally, the therapy has accumulated over 1.9 million patient-years of exposure, providing a substantial body of clinical and real-world evidence supporting its use.
Also Read: How India Became the Pharmacy of the World in a Constrained Economy
The growing adoption of biologics reflects a broader shift toward targeted therapies that address specific inflammatory pathways while potentially reducing systemic effects associated with conventional treatments.
The development is also relevant for India, where awareness and diagnosis of inflammatory bowel diseases have increased significantly over the past decade. Gastroenterologists across major urban centers have reported a steady rise in cases of ulcerative colitis and Crohn’s disease, particularly among younger patients.
India’s IBD treatment market is witnessing sustained growth, driven by improved access to specialty care, increasing healthcare expenditure, and rising demand for biologic therapies. As more patients seek advanced treatment options, global regulatory developments involving innovative therapies such as vedolizumab are closely monitored by clinicians and healthcare stakeholders.
Should the FDA approve ENTYVIO for pediatric use in 2027, it would provide physicians with a new targeted treatment option for children living with chronic gastrointestinal diseases. The decision could also influence future treatment strategies and support the broader adoption of precision medicine approaches in IBD management worldwide.
.jpg)
